YP
RXRX icon

YANKCOM Partnership’s Recursion Pharmaceuticals RXRX Stock Holding History

YANKCOM Partnership’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-300
Closed -$921 – 371
2026
Q1 		$921 Hold
300
– – ﹤0.01% 346
2025
Q4 		$1.23K Buy
+300
New +$1.49K ﹤0.01% 357

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

YANKCOM Partnership's RXRX Position: Q2 2026 in Review

YANKCOM Partnership sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 300 shares — an estimated $921 sold.

YANKCOM Partnership first reported a position in RXRX in Q4 2025 and held it in 2 quarters. The position peaked at $1.23K in Q4 2025. 149 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • YANKCOM Partnership reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • YANKCOM Partnership sold 300 Recursion Pharmaceuticals shares in Q2 2026, an estimated $921.
  • YANKCOM Partnership first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • YANKCOM Partnership's Recursion Pharmaceuticals position peaked at $1.23K in Q4 2025.
  • 149 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on YANKCOM Partnership's 13F filing for Q2 2026, filed 21 Jul 2026.